MX2017013355A - Sales altamente solubles en agua de un bloqueador de canal de calcio de fenilalquilamina, de corta accion y usos de las mismas. - Google Patents

Sales altamente solubles en agua de un bloqueador de canal de calcio de fenilalquilamina, de corta accion y usos de las mismas.

Info

Publication number
MX2017013355A
MX2017013355A MX2017013355A MX2017013355A MX2017013355A MX 2017013355 A MX2017013355 A MX 2017013355A MX 2017013355 A MX2017013355 A MX 2017013355A MX 2017013355 A MX2017013355 A MX 2017013355A MX 2017013355 A MX2017013355 A MX 2017013355A
Authority
MX
Mexico
Prior art keywords
phenylalquilamine
same
highly soluble
soluble water
short action
Prior art date
Application number
MX2017013355A
Other languages
English (en)
Other versions
MX372659B (es
Inventor
P Maguire Martin
Original Assignee
Milestone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57125495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013355(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milestone Pharmaceuticals Inc filed Critical Milestone Pharmaceuticals Inc
Publication of MX2017013355A publication Critical patent/MX2017013355A/es
Publication of MX372659B publication Critical patent/MX372659B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

la presente invención incluye sales sorprendentemente solubles en agua de un compuesto de finilalquilamina que son antagonistas potentes de canales de calcio tipo L. Las soluciones acuosas que incluyen sales de la presente invención se formulan para administración nasal y proporcionan una nueva plataforma terapéutica para el tratamiento de angina estable, migraña y arritmia cardiaca, tal como taquicardia supraventricular paroxística.
MX2017013355A 2015-04-14 2016-04-13 Sales altamente solubles en agua de un bloqueador de canal de calcio de fenilalquilamina, de corta accion y usos de las mismas. MX372659B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147427P 2015-04-14 2015-04-14
PCT/CA2016/050425 WO2016165014A1 (en) 2015-04-14 2016-04-13 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

Publications (2)

Publication Number Publication Date
MX2017013355A true MX2017013355A (es) 2019-01-21
MX372659B MX372659B (es) 2020-03-26

Family

ID=57125495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013355A MX372659B (es) 2015-04-14 2016-04-13 Sales altamente solubles en agua de un bloqueador de canal de calcio de fenilalquilamina, de corta accion y usos de las mismas.

Country Status (28)

Country Link
US (13) US10117848B2 (es)
EP (3) EP4428119A3 (es)
JP (1) JP6785792B2 (es)
KR (3) KR20250057109A (es)
CN (2) CN113694019A (es)
AU (1) AU2016249030B2 (es)
BR (1) BR112017021620B1 (es)
CA (2) CA2982622C (es)
CY (1) CY1122931T1 (es)
DK (1) DK3283067T3 (es)
ES (2) ES2778673T3 (es)
HR (1) HRP20200444T1 (es)
HU (1) HUE049570T2 (es)
IL (1) IL254889B (es)
LT (1) LT3283067T (es)
MA (2) MA46679B1 (es)
MD (1) MD3283067T2 (es)
ME (1) ME03679B (es)
MX (1) MX372659B (es)
PL (2) PL3283067T3 (es)
PT (2) PT3689344T (es)
RS (1) RS60154B1 (es)
RU (1) RU2731918C2 (es)
SI (1) SI3283067T1 (es)
SM (1) SMT202000149T1 (es)
UA (1) UA121330C2 (es)
WO (1) WO2016165014A1 (es)
ZA (2) ZA201706648B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119137A1 (en) 2021-07-15 2023-01-18 Milestone Pharmaceuticals Inc. Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
KR20240147942A (ko) 2023-03-31 2024-10-10 주식회사 엘지화학 오토택신 저해제로서의 신규한 벤즈이미다졸론 유도체 화합물
WO2025215083A1 (en) 2024-04-10 2025-10-16 Dipharma Francis S.R.L. Method for preparing a drug used for paroxysmal supraventricular tachycardia
WO2025229679A1 (en) * 2024-04-30 2025-11-06 Cipla Limited Process for synthesis of etripamil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605074D0 (en) * 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US6831663B2 (en) * 2001-05-24 2004-12-14 Microsoft Corporation System and process for automatically explaining probabilistic predictions
US20050191245A1 (en) 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
US20090318413A1 (en) 2008-06-18 2009-12-24 Universite Victor Segalen Bordeaux 2 Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
IL254889B (en) 2021-07-29
ME03679B (me) 2020-10-20
ES2986137T3 (es) 2024-11-08
US20230414553A1 (en) 2023-12-28
US20250332137A1 (en) 2025-10-30
CY1122931T1 (el) 2021-10-29
EP3283067A4 (en) 2018-12-05
RU2017134553A (ru) 2019-04-05
AU2016249030B2 (en) 2020-08-27
US20230157990A1 (en) 2023-05-25
ES2778673T3 (es) 2020-08-11
KR20250057109A (ko) 2025-04-28
KR20180019508A (ko) 2018-02-26
BR112017021620A2 (pt) 2018-07-03
EP3283067A1 (en) 2018-02-21
CA2982622A1 (en) 2016-10-20
CA3203288A1 (en) 2016-10-20
US20190022048A1 (en) 2019-01-24
HRP20200444T1 (hr) 2020-06-12
US20220040139A1 (en) 2022-02-10
KR102653347B1 (ko) 2024-04-02
NZ736249A (en) 2024-07-05
HUE049570T2 (hu) 2020-10-28
US20200368195A1 (en) 2020-11-26
UA121330C2 (uk) 2020-05-12
US20200121631A1 (en) 2020-04-23
ZA201807495B (en) 2024-04-24
MA46679A (fr) 2018-02-21
CN107613970B (zh) 2021-10-19
PL3689344T3 (pl) 2024-11-04
US20210205258A1 (en) 2021-07-08
HK1249417A1 (en) 2018-11-02
MA52480A (fr) 2022-03-09
KR20240044546A (ko) 2024-04-04
JP6785792B2 (ja) 2020-11-18
SMT202000149T1 (it) 2020-05-08
WO2016165014A1 (en) 2016-10-20
US20250090488A1 (en) 2025-03-20
PT3283067T (pt) 2020-03-31
MX372659B (es) 2020-03-26
LT3283067T (lt) 2020-06-25
EP3283067B1 (en) 2020-01-01
US10117848B2 (en) 2018-11-06
US20240277652A1 (en) 2024-08-22
EP3689344B1 (en) 2024-06-05
DK3283067T3 (da) 2020-03-30
SI3283067T1 (sl) 2020-07-31
IL254889A0 (en) 2017-12-31
JP2018514527A (ja) 2018-06-07
ZA201706648B (en) 2020-01-29
AU2016249030A1 (en) 2017-10-26
MA46679B1 (fr) 2020-04-30
RU2017134553A3 (es) 2019-11-13
CN113694019A (zh) 2021-11-26
MD3283067T2 (ro) 2020-05-31
PL3283067T3 (pl) 2020-09-21
US20190269643A1 (en) 2019-09-05
EP3689344A1 (en) 2020-08-05
RU2731918C2 (ru) 2020-09-09
CN107613970A (zh) 2018-01-19
CA2982622C (en) 2023-08-22
EP4428119A3 (en) 2024-11-13
US20180110752A1 (en) 2018-04-26
RS60154B1 (sr) 2020-05-29
PT3689344T (pt) 2024-09-04
EP4428119A2 (en) 2024-09-11
US20220296556A1 (en) 2022-09-22
BR112017021620B1 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CO2019008487A2 (es) Compuesto de quinazolina
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
MX385687B (es) Inhibidores de calicreína plasmática humana.
MX2018004664A (es) Antagonistas de ep4.
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
MX2017013355A (es) Sales altamente solubles en agua de un bloqueador de canal de calcio de fenilalquilamina, de corta accion y usos de las mismas.
PE20170430A1 (es) Arilhidrazidas que contienen una fraccion de 2-piridona como agentes antibacterianos selectivos
MX2018003381A (es) Profilactico o agente terapeutico para queratitis fungica.
PH12016502527B1 (en) Stabilized desmopressin
BR112017016393A2 (pt) composições farmacêuticas estáveis compreendendo agente antibacteriano
AR132461A2 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA202091668A2 (ru) Ингибиторы калликреина плазмы человека
NZ780408A (en) Human plasma kallikrein inhibitors
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза

Legal Events

Date Code Title Description
FG Grant or registration